Clinical Viewpoints
Ten common errors in the management of inflammatory bowel disease
David B. Sachar M.D., F.A.C.P., M.A.C.G.,
Robert Burakoff M.D., M.P.H.,
Richard P. MacDermott M.D.,
Corresponding Author
David B. Sachar M.D., F.A.C.P., M.A.C.G.
Division of Gastroenterology, Brighan and Women's Hospital, 45 Francis Street, Boston, MA 02115
Division of GI, Mount Sinai School of Medicine, One Gustave L. Levy Place—Box 1069, New York, NY 10029, U.S.A.Search for more papers by this authorRobert Burakoff M.D., M.P.H.
Division of Gastroenterology, Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208-3479
Search for more papers by this authorRichard P. MacDermott M.D.
Mount Sinai School of Medicine, New York, New York, U.S.A.
Search for more papers by this authorDavid B. Sachar M.D., F.A.C.P., M.A.C.G.,
Robert Burakoff M.D., M.P.H.,
Richard P. MacDermott M.D.,
Corresponding Author
David B. Sachar M.D., F.A.C.P., M.A.C.G.
Division of Gastroenterology, Brighan and Women's Hospital, 45 Francis Street, Boston, MA 02115
Division of GI, Mount Sinai School of Medicine, One Gustave L. Levy Place—Box 1069, New York, NY 10029, U.S.A.Search for more papers by this authorRobert Burakoff M.D., M.P.H.
Division of Gastroenterology, Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208-3479
Search for more papers by this authorRichard P. MacDermott M.D.
Mount Sinai School of Medicine, New York, New York, U.S.A.
Search for more papers by this authorFirst published: 14 December 2006
References
- 1 Bayless TM, Harris ML. Inflammatory bowel disease and irritable bowel syndrome. Med Clin N Am 1990; 74: 21–8.
- 2 Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993; 118: 540–9.
- 3 Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987; 317: 1625–9.
- 4 Singleton J, Gitnick G, Hanauer S, et al. Response of Crohn's disease to oral Pentasa (controlled release mesalamine) as a function of disease location and prior therapy: results of a multicenter study. Gastroenterology 1993; 104: 1293–1300.
- 5 Sachar DB. Maintenance therapy in ulcerative colitis and Crohn's disease. J Clin Gastroenterol 1995; 20: 117–22.
- 6 Safdi M, deMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92: 1867–71.
- 7 D'Albasio G, Pacini F, Cawam E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997; 92: 1143–7.
- 8 Present DH. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000; 6: 48–57.
- 9 Sylvester FA, Hyams JS. Appropriate use of corticosteroids in inflammatory bowel disease. In: TM Bayless, SB Hanauer, eds. Advanced Therapy for Inflammatory Bowel Disease. London: BC Decker; 2001: 363–66.
- 10 Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance in Crohn's disease: a placebo-controlled dose-ranging study. Gastroenterology 1996; 110: 45–51.
- 11 Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine with prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895–902.
- 12 Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporine in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94: 1587–92.
- 13 Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide. Am J Gastroenterol 2002; 97: 2962–72.
- 14 Colonna T, Korelitz BI. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 1994; 89: 362–6.
- 15 Modigliani R. Immunosuppressors for inflammatory bowel disease: how long is long enough? Inflamm Bowel Dis 2000; 6: 251–7.
- 16 Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124: 9–17.
- 17 Feagan BG, Rochou J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332: 292–7.
- 18 Feagan BG, Fedorak RN, Irvine EJ, et al. Comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med 2000; 342: 1627–32.
- 19 Baert F, Noman M, Vermeire K, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601–8.
- 20 Kornbluth A. Cyclosporine in inflammatory bowel disease. Curr Gastroenterol Rep 1999; 1: 486–90.
- 21 Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep vein thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001; 85: 430–4.
- 22 Mogan GR, Sachar DB, Bauer J, et al. Toxic megacolon in ulcerative colitis complicated by pneumomediastinum: report of two cases. Gastroenterology 1980; 79: 159–62.
- 23 Greenstein AJ, Sachar DB, Gibas A, et al. Outcome of toxic dilation in ulcerative and Crohn's colitis. J Clin Gastroenterol 1985; 7: 137–43.
- 24 Rubin PH, Friedman S, Harpaz N, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 1999; 117: 1295–1300.
- 25 Engelsgjed M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology 1999; 117: 1288–94.
- 26 Lindberg B, Persson H, Veress H, et al. Twenty years' colonoscopic surveillance of patients with ulcerative colitis: detection of dysplastic and malignant transformation. Scand J Gastroenterol 1996; 31: 1195–1204.
- 27 Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994; 107: 934–44.
- 28 Ullman TA. Loftus Jr, EV Kakar S, et al. The fate of low grade dysplasia in ulcerative colitis. Am J Gastroetnerol 2002; 97: 922–7.
- 29 Sachar DB. Indications for surgery in inflammatory bowel disease: a gastroetnerologist's opinion. In: JB Kirsner, ed. Inflammatory Bowel Disease. 5th ed. Philadelphia: Saunders; 2000: 611–5.
